These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 36614011)

  • 21. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.
    Huang W; Chen YY; Li ZQ; He FF; Zhang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms.
    Xu C; Ha X; Yang S; Tian X; Jiang H
    Front Endocrinol (Lausanne); 2023; 14():1232790. PubMed ID: 37859992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease.
    Klein J; Caubet C; Camus M; Makridakis M; Denis C; Gilet M; Feuillet G; Rascalou S; Neau E; Garrigues L; Thillaye du Boullay O; Mischak H; Monsarrat B; Burlet-Schiltz O; Vlahou A; Saulnier-Blache JS; Bascands JL; Schanstra JP
    Sci Rep; 2020 Sep; 10(1):14898. PubMed ID: 32913274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel pharmacological interventions for diabetic kidney disease.
    Tan SK; Pinzon-Cortes JA; Cooper ME
    Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):13-25. PubMed ID: 37889557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
    Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
    Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Stephens JW; Brown KE; Min T
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the identification and management of diabetic nephropathy in patients with diabetes in primary care.
    Picow E
    J Am Assoc Nurse Pract; 2023 Nov; 35(11):740-746. PubMed ID: 37471566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for kidney disease in people with diabetes mellitus.
    van Raalte DH; Bjornstad P; Cherney DZI; de Boer IH; Fioretto P; Gordin D; Persson F; Rosas SE; Rossing P; Schaub JA; Tuttle K; Waikar SS; Heerspink HJL
    Nat Rev Nephrol; 2024 Jul; 20(7):433-446. PubMed ID: 38570632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease.
    Zhang X; Zhou Y; Ma R
    J Diabetes Complications; 2022 Jan; 36(1):108056. PubMed ID: 34893426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
    Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
    Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
    Mou Y; Zhang Y; Guo C; Zhao J; Zhang Z; Zhou X; Dong J; Liao L
    DNA Cell Biol; 2018 Feb; 37(2):133-141. PubMed ID: 29185789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies to tackle diabetic kidney disease.
    Batu Demir D; Cooper ME
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.